Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024
Lyell Immunopharma, Inc. (LYEL)
Company Research
Source: GlobeNewswire
Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell product candidate, this quarterOn track to report initial clinical data from the Phase 1 trial of LYL845, an epigenetically enhanced TIL product candidate, in the second half of 2024IND for second generation ROR1-targeted CAR T-cell product candidate on track for submission this quarterCash, cash equivalents and marketable securities of $526.3 million as of March 31, 2024 supports advancing diverse pipeline through multiple clinical milestones into 2027 SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors today reported financial results and business highlights for the first quarter ended March 31, 2024. “The initial clinical and translational data from the Phase 1 trial of LYL797, our lead CAR
Show less
Read more
Impact Snapshot
Event Time:
LYEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LYEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LYEL alerts
High impacting Lyell Immunopharma, Inc. news events
Weekly update
A roundup of the hottest topics
LYEL
News
- Lyell Immunopharma to Participate in BofA Securities Health Care Conference [Yahoo! Finance]Yahoo! Finance
- Lyell Immunopharma to Participate in BofA Securities Health Care ConferenceGlobeNewswire
- Lyell Immunopharma, Inc. (NASDAQ: LYEL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024 [Yahoo! Finance]Yahoo! Finance
- Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts [Seeking Alpha]Seeking Alpha
LYEL
Analyst Actions
- 5/7/24 - HC Wainwright
LYEL
Sec Filings
- 5/6/24 - Form 424B5
- 5/6/24 - Form 10-Q
- 5/6/24 - Form 8-K
- LYEL's page on the SEC website